(ILM1) Medios - Ratings and Ratios
Pharmaceuticals, Oncology, Neurology, Autoimmunology, Ophthalmology
ILM1 EPS (Earnings per Share)
ILM1 Revenue
Description: ILM1 Medios
Medios AG is a German healthcare company that specializes in supplying specialty pharmaceutical drugs, primarily operating in Germany. The company operates through two main segments: Pharmaceutical Supply and Patient-Specific Therapies. The Pharmaceutical Supply segment offers a range of products for various diseases, including oncology, neurology, and hemophilia. The Patient-Specific Therapies segment manufactures customized medications for patients on behalf of pharmacies, including cytostatic infusion preparations and parenteral nutrition solutions.
From a business perspective, Medios AG has a relatively niche focus on specialty pharmaceuticals, which can provide a competitive edge. The companys revenue growth is likely driven by the demand for its products in the German market. To further analyze the companys performance, key performance indicators (KPIs) such as revenue growth rate, gross margin, and operating margin can be examined. For instance, a high gross margin could indicate the companys ability to maintain pricing power and manage its cost of goods sold effectively.
In terms of valuation, Medios AG has a market capitalization of 320.36M EUR, with a P/E ratio of 21.15 and a forward P/E ratio of 7.87. The significant difference between the current and forward P/E ratios suggests that the market expects a substantial increase in earnings in the future. Additionally, the companys Return on Equity (RoE) is 2.93%, which is relatively low. To improve profitability, Medios AG may need to focus on optimizing its operational efficiency and improving its asset utilization.
To gain a deeper understanding of Medios AGs financial health, other KPIs such as debt-to-equity ratio, interest coverage ratio, and cash conversion cycle can be analyzed. For example, a low debt-to-equity ratio could indicate a healthy balance sheet, while a high interest coverage ratio could suggest the companys ability to service its debt. By examining these KPIs, a more comprehensive picture of Medios AGs financial performance and potential for future growth can be formed.
ILM1 Stock Overview
| Market Cap in USD | 438m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception |
ILM1 Stock Ratings
| Growth Rating | -45.9% |
| Fundamental | 62.1% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -24.1% |
| Analyst Rating | - |
ILM1 Dividends
Currently no dividends paidILM1 Growth Ratios
| Growth Correlation 3m | 86.1% |
| Growth Correlation 12m | -31.5% |
| Growth Correlation 5y | -93% |
| CAGR 5y | -8.48% |
| CAGR/Max DD 3y | -0.17 |
| CAGR/Mean DD 3y | -0.31 |
| Sharpe Ratio 12m | -0.11 |
| Alpha | -20.49 |
| Beta | 0.394 |
| Volatility | 34.36% |
| Current Volume | 20.7k |
| Average Volume 20d | 20.7k |
| Stop Loss | 14.1 (-4.3%) |
| Signal | -0.31 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (18.8m TTM) > 0 and > 6% of Revenue (6% = 118.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -7.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.45% (prev -0.68%; Δ 9.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 63.0m > Net Income 18.8m (YES >=105%, WARN >=100%) |
| Net Debt (-87.8m) to EBITDA (81.4m) ratio: -1.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (25.5m) change vs 12m ago 4.39% (target <= -2.0% for YES) |
| Gross Margin 9.73% (prev 3.62%; Δ 6.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 212.7% (prev 197.2%; Δ 15.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.20 (EBITDA TTM 81.4m / Interest Expense TTM 13.5m) >= 6 (WARN >= 3) |
Altman Z'' 2.14
| (A) 0.18 = (Total Current Assets 346.3m - Total Current Liabilities 180.2m) / Total Assets 918.1m |
| (B) 0.10 = Retained Earnings (Balance) 91.1m / Total Assets 918.1m |
| (C) 0.05 = EBIT TTM 43.3m / Avg Total Assets 925.2m |
| (D) 0.30 = Book Value of Equity 116.6m / Total Liabilities 394.8m |
| Total Rating: 2.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 62.06
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 10.46% = 5.0 |
| 3. FCF Margin 2.82% = 0.71 |
| 4. Debt/Equity 0.47 = 2.39 |
| 5. Debt/Ebitda 3.02 = -1.79 |
| 6. ROIC - WACC -0.34% = -0.43 |
| 7. RoE 3.66% = 0.30 |
| 8. Rev. Trend 85.44% = 6.41 |
| 9. EPS Trend -0.72% = -0.04 |
What is the price of ILM1 shares?
Over the past week, the price has changed by +0.00%, over one month by +3.66%, over three months by +29.75% and over the past year by -9.79%.
Is Medios a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ILM1 is around 14.06 EUR . This means that ILM1 is currently overvalued and has a potential downside of -4.61%.
Is ILM1 a buy, sell or hold?
What are the forecasts/targets for the ILM1 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.5 | 66.2% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 15.2 | 2.8% |
ILM1 Fundamental Data Overview
Market Cap EUR = 373.4m (373.4m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 87.8m EUR (Cash And Short Term Investments, last quarter)
P/E Trailing = 19.7838
P/E Forward = 7.874
P/S = 0.1898
P/B = 0.7136
Beta = 1.319
Revenue TTM = 1.97b EUR
EBIT TTM = 43.3m EUR
EBITDA TTM = 81.4m EUR
Long Term Debt = 214.6m EUR (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 31.0m EUR (from shortTermDebt, last quarter)
Debt = 245.6m EUR (Calculated: Short Term 31.0m + Long Term 214.6m)
Net Debt = -87.8m EUR (from netDebt column, last quarter)
Enterprise Value = 531.2m EUR (373.4m + Debt 245.6m - CCE 87.8m)
Interest Coverage Ratio = 3.20 (Ebit TTM 43.3m / Interest Expense TTM 13.5m)
FCF Yield = 10.46% (FCF TTM 55.6m / Enterprise Value 531.2m)
FCF Margin = 2.82% (FCF TTM 55.6m / Revenue TTM 1.97b)
Net Margin = 0.96% (Net Income TTM 18.8m / Revenue TTM 1.97b)
Gross Margin = 9.73% ((Revenue TTM 1.97b - Cost of Revenue TTM 1.78b) / Revenue TTM)
Tobins Q-Ratio = 4.56 (Enterprise Value 531.2m / Book Value Of Equity 116.6m)
Interest Expense / Debt = 1.03% (Interest Expense 2.52m / Debt 245.6m)
Taxrate = 42.58% (9.30m / 21.9m)
NOPAT = 24.8m (EBIT 43.3m * (1 - 42.58%))
Current Ratio = 1.92 (Total Current Assets 346.3m / Total Current Liabilities 180.2m)
Debt / Equity = 0.47 (Debt 245.6m / last Quarter total Stockholder Equity 523.3m)
Debt / EBITDA = 3.02 (Net Debt -87.8m / EBITDA 81.4m)
Debt / FCF = 4.42 (Debt 245.6m / FCF TTM 55.6m)
Total Stockholder Equity = 514.4m (last 4 quarters mean)
RoA = 2.05% (Net Income 18.8m, Total Assets 918.1m )
RoE = 3.66% (Net Income TTM 18.8m / Total Stockholder Equity 514.4m)
RoCE = 5.93% (Ebit 43.3m / (Equity 514.4m + L.T.Debt 214.6m))
RoIC = 4.40% (NOPAT 24.8m / Invested Capital 564.7m)
WACC = 4.74% (E(373.4m)/V(619.0m) * Re(7.47%)) + (D(245.6m)/V(619.0m) * Rd(1.03%) * (1-Tc(0.43)))
Shares Correlation 3-Years: 82.65 | Cagr: 0.74%
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈82.3m ; Y1≈54.0m ; Y5≈24.7m
Fair Price DCF = 19.05 (DCF Value 485.8m / Shares Outstanding 25.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -0.72 | EPS CAGR: 6.55% | SUE: 2.09 | # QB: True
Revenue Correlation: 85.44 | Revenue CAGR: 7.16%